Literature DB >> 21553105

Carbohydrate antigen 242 highly consists with carbohydrate antigen 19-9 in diagnosis and prognosis of colorectal cancer: study on 185 cases.

Xue-Qin Yang1, Chuang Chen, Chun-Wei Peng, Shao-Ping Liu, Yan Li.   

Abstract

The objective of the study was to compare the clinical value of preoperative serum carbohydrate antigen 19-9 (CA19-9) and carbohydrate antigen 242 (CA242) in diagnosis and prognosis for 5-year recurrence-free survival (RFS) in patients with colorectal cancer (CRC). Preoperative serum CA19-9 and CA242 concentrations were detected by C12 protein chip diagnostic system in 185 patients with CRC, and informative data were collected during 5-year follow-up periods. The value of CA19-9 and CA242 in diagnosis and prognosis for 5-year RFS as well as their consistencies and correlations were comparatively analyzed. The sensitivities of CA19-9 and CA242 were only 19.5 and 20%, respectively; the efficiencies of two TMs were 53.9 and 54.2%, respectively; and two TMs increased significantly with advancing clinical stages (P < 0.0001). Preoperative CA19-9 and CA242 levels correlated with stage (r, 0.411 and 0.408) and CEA concentration (r, 0.553 and 0.630). The concentrations of two TMs closely correlated with each other (r = 0.829), and two TMs had a very strong consistency in diagnosis (κ = 0.931). Among 88 of 185 cases with complete follow-up information on RFS, patients with positive preoperative serum CA19-9 or CA242 had higher 5-year recurrent rates (72.2% vs. 44.3%, P = 0.034; 76.5% vs. 43.7%, P = 0.015) and reduced median RFS (14 vs. 36 months, 12 vs. 36 months) compared with those with negative TMs. The consistency of predicting prognosis for RFS of two TMs was extremely strong (κ = 0.964). ROC curves analysis showed that CA242 test performed better than CA19-9 test (AUC, 0.648 vs. 0.605). Univariate analysis showed that preoperative serum status of both TMs was correlated with 5-year RFS (P < 0.05), whereas multivariate Cox regression model analysis revealed that none of them were independent prognostic factors for RFS. Both CA19-9 and CA242 had strong consistencies in diagnosis and prognosis for predicting 5-year RFS. CA242 demonstrated superior value to CA19-9 in CRC.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21553105     DOI: 10.1007/s12032-011-9967-z

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  20 in total

1.  Evaluation of the CA 242 tumor antigen as a potential serum marker for colorectal cancer.

Authors:  A Spila; P Ferroni; M Cosimelli; R D'Alessandro; M D Carone; S Aloe; M Tedesco; R Mancini; V Casale; S Carlini; C U Casciani; M Roselli; F Guadagni
Journal:  Anticancer Res       Date:  1999 Mar-Apr       Impact factor: 2.480

2.  Application of C12 multi-tumor marker protein chip in the diagnosis of gastrointestinal cancer: results of 329 surgical patients and suggestions for improvement.

Authors:  Xue-Qin Yang; Li Yan; Chuang Chen; Jin-Xuan Hou; Yan Li
Journal:  Hepatogastroenterology       Date:  2009 Sep-Oct

3.  Tumor markers in staging and prognosis of colorectal carcinoma.

Authors:  M Levy; V Visokai; L Lipska; O Topolcan
Journal:  Neoplasma       Date:  2008       Impact factor: 2.575

4.  A monoclonal antibody-defined antigen associated with gastrointestinal cancer is a ganglioside containing sialylated lacto-N-fucopentaose II.

Authors:  J L Magnani; B Nilsson; M Brockhaus; D Zopf; Z Steplewski; H Koprowski; V Ginsburg
Journal:  J Biol Chem       Date:  1982-12-10       Impact factor: 5.157

5.  Relationship between peripheral and mesenteric serum levels of CEA and CA 242 with staging and histopathological variables in colorectal adenocarcinoma.

Authors:  Mauro Lamelas Cardoso; Luís Cesar Fernandes; Su Bong Kim; Delcio Matos
Journal:  Acta Cir Bras       Date:  2009 Sep-Oct       Impact factor: 1.388

6.  Comparison of a new tumour marker CA 242 with CA 19-9, CA 50 and carcinoembryonic antigen (CEA) in digestive tract diseases.

Authors:  P Kuusela; C Haglund; P J Roberts
Journal:  Br J Cancer       Date:  1991-04       Impact factor: 7.640

7.  Assessment of the value of preoperative serum levels of CA 242 and CEA in the staging and postoperative survival of colorectal adenocarcinoma patients.

Authors:  S B Kim; L C Fernandes; S S Saad; D Matos
Journal:  Int J Biol Markers       Date:  2003 Jul-Sep       Impact factor: 3.248

8.  Preoperative serum levels of CEA and CA 242 in colorectal cancer.

Authors:  M Carpelan-Holmström; C Haglund; P Kuusela; H Järvinen; P J Roberts
Journal:  Br J Cancer       Date:  1995-04       Impact factor: 7.640

9.  CA 242, a new tumour marker for pancreatic cancer: a comparison with CA 19-9, CA 50 and CEA.

Authors:  C Haglund; J Lundin; P Kuusela; P J Roberts
Journal:  Br J Cancer       Date:  1994-09       Impact factor: 7.640

10.  Independent prognostic value of preoperative serum markers CA 242, specific tissue polypeptide antigen and human chorionic gonadotrophin beta, but not of carcinoembryonic antigen or tissue polypeptide antigen in colorectal cancer.

Authors:  M Carpelan-Holmström; C Haglund; J Lundin; H Alfthan; U H Stenman; P J Roberts
Journal:  Br J Cancer       Date:  1996-09       Impact factor: 7.640

View more
  7 in total

1.  Nodule and eminence on frenulum labii superioris: diagnostic markers for metastatic colorectal cancer.

Authors:  Rui Cao; Li-ping Wang; Jia-dong Chi; Xiong-zhi Wu
Journal:  Chin J Integr Med       Date:  2014-06-21       Impact factor: 1.978

2.  Circulating Methylated SEPT9 DNA Analyses to Predict Recurrence Risk and Adjuvant Chemotherapy Benefit in Stage II to III Colorectal Cancer.

Authors:  Zhen Yuan; Shuyuan Wang; Kemin Ni; Yixiang Zhan; Hong Ma; Xinyu Liu; Ran Xin; Xingyu Zhou; Zhaoce Liu; Xuanzhu Zhao; Xin Yin; Hangyu Ping; Yaohong Liu; Wanting Wang; Suying Yan; Qiurong Han; Wei Cui; Xipeng Zhang; Qinghuai Zhang; Chunze Zhang
Journal:  Med Sci Monit       Date:  2022-09-19

Review 3.  Chinese expert consensus on cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal malignancies.

Authors:  Yan Li; Yun-Feng Zhou; Han Liang; Hua-Qing Wang; Ji-Hui Hao; Zheng-Gang Zhu; De-Seng Wan; Lun-Xiu Qin; Shu-Zhong Cui; Jia-Fu Ji; Hui-Mian Xu; Shao-Zhong Wei; Hong-Bin Xu; Tao Suo; Shu-Jun Yang; Cong-Hua Xie; Xiao-Jun Yang; Guo-Liang Yang
Journal:  World J Gastroenterol       Date:  2016-08-14       Impact factor: 5.742

4.  Combined detection of preoperative serum CEA, CA19-9 and CA242 improve prognostic prediction of surgically treated colorectal cancer patients.

Authors:  Jingtao Wang; Xiao Wang; Fudong Yu; Jian Chen; Senlin Zhao; Dongyuan Zhang; Yang Yu; Xisheng Liu; Huamei Tang; Zhihai Peng
Journal:  Int J Clin Exp Pathol       Date:  2015-11-01

5.  Predictive values of multidetector-row computed tomography combined with serum tumor biomarkers in preoperative lymph node metastasis of gastric cancer.

Authors:  Huihui Bai; Jingyu Deng; Nannan Zhang; Huifang Liu; Wenting He; Jinyuan Liu; Han Liang
Journal:  Chin J Cancer Res       Date:  2019-06       Impact factor: 5.087

6.  FOLFOX regimen plus dendritic cells-cytokine-induced killer cells immunotherapy for the treatment of colorectal cancer: a meta-analysis.

Authors:  Yan Liu; Zhong Zheng; Qixin Zhang; Xinling Zhou; Yikuan Feng; Anquan Yan
Journal:  Onco Targets Ther       Date:  2017-05-18       Impact factor: 4.147

7.  PUM1 is upregulated by DNA methylation to suppress antitumor immunity and results in poor prognosis in pancreatic cancer.

Authors:  Yishi Yang; Xingxing Su; Kaicheng Shen; Chengcheng Zhang; Haisu Dai; Hongbo Ma; Yan Jiang; Ling Shuai; Zhipeng Liu; Jinshan You; Ke Min; Zhiyu Chen
Journal:  Transl Cancer Res       Date:  2021-05       Impact factor: 1.241

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.